{"id":34236,"date":"2025-04-04T10:14:48","date_gmt":"2025-04-04T14:14:48","guid":{"rendered":"https:\/\/advisory.avalerehealth.com\/?p=34236"},"modified":"2025-04-04T10:14:48","modified_gmt":"2025-04-04T14:14:48","slug":"new-resource-commercial-payers-use-of-oncology-compendia","status":"publish","type":"post","link":"https:\/\/advisory.avalerehealth.com\/insights\/new-resource-commercial-payers-use-of-oncology-compendia","title":{"rendered":"New Resource: Commercial Payers\u2019 Use of Oncology Compendia"},"content":{"rendered":"

Payers use clinical drug compendia (NCCN, AHFS, Clinical Pharmacology, DrugDex, DrugPoints, Lexi Drugs) to classify drugs and biologics in formularies and to guide medical appropriateness of use. The compendia for Medicare and Medicaid are in federal law, while the compendia for commercial payers vary based on the states in which they operate and their own coverage rules. Commercial payers\u2019<\/a> utilization of clinical drug compendia is not available in one place, making it difficult to understand the impact on patient access.<\/p>\n

Avalere created the Payers\u2019 Overarching Compendia Policies Dashboard to track off-label oncology coverage trends across the top 50 commercial payers, cumulatively covering over 160 million lives. The goal of this resource is to help manufacturers navigate coverage challenges and anticipate access barriers.<\/p>\n

The dashboard identifies which compendia are referenced by plans, alignment with Centers for Medicare and Medicaid (CMS)-recognized sources, and how evidence ratings influence coverage. The dashboard includes trends in policies from 37 of the top 50 payers, representing 127 million covered lives.<\/p>\n

Users can filter by compendium rating (e.g., National Comprehensive Cancer Network [NCCN] Category 2B) to assess coverage variations, supporting market access strategies, payer engagement, and denial analysis. Users can also filter by payer to see the evidence ratings the payer requires for coverage, which can support evidence generation\/submission for denied claim appeals.<\/p>\n

Most (74%) of payers mention one or more compendia in coverage policies. Among 37 payers with overarching policies, only three strictly follow CMS compendia and ratings, and four do not reference NCCN. \u00a0The Avalere dashboard also provides insights into geographic trends via an integrated heatmap, illustrating state-specific coverage.<\/p>\n

Payer-specific interpretations of compendia create coverage disparities, leading to treatment delays. This dashboard helps stakeholders anticipate restrictions and understand evolving policies.<\/p>\n

The Payers\u2019 Overarching Compendia Policies Dashboard answers key questions, including:<\/p>\n